Clemastine ( DrugBank: Clemastine )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
13多発性硬化症/視神経脊髄炎6

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05359653
(ClinicalTrials.gov)
March 22, 202328/4/2022Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair TherapyA Randomized, Double-Blind, Delayed Treatment, Placebo-Controlled Trial to Assess the Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair TherapyMultiple Sclerosis (MS);Multiple Sclerosis, Relapsing-Remitting;Multiple Sclerosis, Primary Progressive;Multiple Sclerosis, Chronic Progressive;Multiple Sclerosis Relapse;Multiple Sclerosis Brain Lesion;Multiple Sclerosis BenignDrug: Clemastine Fumarate;Drug: PlaceboUniversity of California, San FranciscoUnited States Department of DefenseNot yet recruiting18 Years55 YearsAll74Phase 1/Phase 2United States
2NCT05338450
(ClinicalTrials.gov)
August 30, 20226/4/2022Clemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple SclerosisClemastine Fumarate as Remyelinating Treatment in Internuclear Ophthalmoparesis and Multiple SclerosisMultiple Sclerosis;Internuclear OphthalmoplegiaDrug: Clemastine Fumarate;Drug: PlaceboAmsterdam UMC, location VUmcNULLRecruiting18 Years70 YearsAll80Phase 3Netherlands
3NCT05131828
(ClinicalTrials.gov)
March 8, 202212/11/2021CCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying TherapyCCMR Two: A Phase IIa, Randomised, Double-blind, Placebo-controlled Trial of the Ability of the Combination of Metformin and Clemastine to Promote Remyelination in People With Relapsing-remitting Multiple Sclerosis Already on Disease-modifying TherapyMultiple SclerosisDrug: Metformin and clemastine in combination;Drug: PlaceboCambridge University Hospitals NHS Foundation TrustUniversity of CambridgeRecruiting25 Years50 YearsAll50Phase 2United Kingdom
4EUCTR2021-003677-66-NL
(EUCTR)
14/02/202216/12/2021Clemastine fumarate as a treament for eye movement disorders in patients with multiple sclerosisClemastine fumarate as remyelinating treatment in internuclear ophthalmoparesis and multiple sclerosis - RESTORE Multiple sclerosis (MS)Internuclear ophthalmoparesis (INO)
MedDRA version: 21.0;Level: LLT;Classification code 10080865;Term: Multiple sclerosis lesion;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Clemastine Milstein 1 mg, tabletten
Product Name: Clemastine fumarate
INN or Proposed INN: CLEMASTINE FUMARATE
Trade Name: Fampyra 10 mg prolonged-release tablets
Product Name: Fampridine
INN or Proposed INN: Fampridine
Amsterdam University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
80Phase 3Netherlands
5NCT03109288
(ClinicalTrials.gov)
August 11, 201711/4/2017Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)Multiple SclerosisDrug: Pioglitazone;Drug: clemastine fumarate;Drug: Dantrolene;Drug: PirfenidoneNational Institute of Allergy and Infectious Diseases (NIAID)NULLRecruiting18 YearsN/AAll250Phase 1/Phase 2United States
6NCT02040298
(ClinicalTrials.gov)
January 201410/1/2014Assessment of Clemastine Fumarate as a Remyelinating Agent in Multiple SclerosisA Phase II Randomized, Double-Blind, Parallel-Group, Placebo Controlled Crossover Trial to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Clemastine Fumarate as a Remyelinating Agent in Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingDrug: Clemastine;Drug: PlaceboUniversity of California, San FranciscoNULLCompleted18 Years60 YearsBoth50Phase 2United States